Myogenes Clozapine Test promises to improve outcomes for schizophrenia patients

FHS
October 4, 2024
11:34 am

Myogenes, a leading innovator in genetic testing, has been awarded a grant from Innovate UK, the UK’s innovation agency, to further develop its revolutionary Myogenes Clozapine Test for treatment-resistant schizophrenia (TRS). This cutting-edge genetic analysis tool promises to dramatically improve patient care and generate substantial cost savings for the NHS.

Kate Therapeutics launches with $51M to develop genetic medicines for muscle and heart diseases

Gene therapy company Kate Therapeutics Inc. (KateTx), has emerged from stealth mode with a $51 million Series A financing. In addition, the company has granted

June 8, 2023

New research reveals how social isolation impacts behavior and lifespan in social species

Researchers used Camponotus fellah (carpenter ants) as a model species to perform behavioral tracking and ribonucleic acid-sequencing (RNA-seq) to study the transcriptome-level differences between socially isolated

September 29, 2023

Opinion | ‘That’s a Society-Ending Pandemic’: What We Heard This Week

“That’s a society-ending pandemic.” — James Lawler, MD, MPH, of the University of Nebraska Medical Center’s Global Center for Health Security, on viruses with high

April 29, 2024

Supercharge Your Portfolio with Future Health Stocks!

Join us for Profitable Insights & Expert Tips!

With expert analysis, comprehensive market coverage, and actionable insights, our newsletter equips you with the knowledge & tools necessary to make informed decisions & maximize your potential returns in the dynamic world of future health stocks.